Solvias, an independent pharmaceutical testing and manufacturing company, has acquired Netherlands-based Cergentis. Cergentis is a genomics-focused biotechnology company providing services and in-house solutions based on its proprietary genomic analysis platform. The acquisition bolsters Solvias’ platform of biologics and cell and gene therapy (CGT) testing solutions and supports the increasing number of global pharmaceutical, biotech, and contract…
Home Healthcare Markets International News Switzerland: Solvias bolsters biologics and cell & gene therapy capabilities with Cergentis